No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62)
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG plus lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (interquartile range) total and unbound DTG in CSF were 7.3 (5.9-8.4) and 1.7 (1.2-1.9) ng/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory/injury markers within the CNS reservoir.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:223 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 223(2021), 11 vom: 04. Juni, Seite 1928-1933 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tiraboschi, Juan M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.02.2022 Date Revised 11.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiaa645 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316186953 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316186953 | ||
| 003 | DE-627 | ||
| 005 | 20231225160535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiaa645 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316186953 | ||
| 035 | |a (NLM)33049035 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tiraboschi, Juan M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2022 | ||
| 500 | |a Date Revised 11.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG plus lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (interquartile range) total and unbound DTG in CSF were 7.3 (5.9-8.4) and 1.7 (1.2-1.9) ng/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory/injury markers within the CNS reservoir | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CNS | |
| 650 | 4 | |a concentrations | |
| 650 | 4 | |a dolutegravir | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a lamivudine | |
| 650 | 4 | |a neuronal damage | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
| 650 | 7 | |a Oxazines |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 700 | 1 | |a Rojas, Jhon |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, Kaj |e verfasserin |4 aut | |
| 700 | 1 | |a Niubo, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Gostner, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro-Alcaraz, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Piatti, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Dietmar |e verfasserin |4 aut | |
| 700 | 1 | |a Gisslén, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Rigo-Bonnin, Raul |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Podzamczer, Daniel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 223(2021), 11 vom: 04. Juni, Seite 1928-1933 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:223 |g year:2021 |g number:11 |g day:04 |g month:06 |g pages:1928-1933 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiaa645 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 223 |j 2021 |e 11 |b 04 |c 06 |h 1928-1933 | ||